Difference between revisions of "Pemigatinib (Pemazyre)"
Jump to navigation
Jump to search
m |
|||
| Line 11: | Line 11: | ||
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
| − | *3/26/2021: Initial | + | *3/26/2021: Initial conditional authorization as Pemazyre. |
==Also known as== | ==Also known as== | ||
Revision as of 02:15, 31 December 2022
General information
Class/mechanism from the NCI Drug Dictionary: An orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) types 1, 2, and 3 (FGFR1/2/3), with potential antineoplastic activity. Pemigatinib binds to and inhibits FGFR1/2/3, which may result in the inhibition of FGFR1/2/3-related signal transduction pathways. This inhibits proliferation in FGFR1/2/3-overexpressing tumor cells.
Diseases for which it is used
History of changes in FDA indication
- 4/17/2020: Granted accelerated approval for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement. (Based on FIGHT-202)
- 8/26/2022: Approved for adults with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement. (Based on FIGHT-203)
History of changes in EMA indication
- 3/26/2021: Initial conditional authorization as Pemazyre.
Also known as
- Code name: INCB054828
- Brand name: Pemazyre